Express News | CASI Pharmaceuticals: Accrual to Phase 1-2 Study of Cid-103 Expected to Commence in Q1 2025

ReutersDec 26 08:32 ET

Express News | CASI Pharmaceuticals: Cid-103 Ind Application Supporting Phase 1-2 Study of Cid-103 in Adults With Chronic Immune Thrombocytopenia Remains Open

ReutersDec 26 08:32 ET

Express News | CASI Pharmaceuticals: FDA Plans to Provide Formal Written Response Before Statutory Deadline

ReutersDec 26 08:31 ET

Express News | CASI Pharmaceuticals Inc: Announces Clinical Hold of Cid-103 for Antibody Mediated Rejection (Amr) of Kidney Transplant

ReutersDec 26 08:30 ET

Express News | CASI Pharmaceuticals Inc Files for Mixed Shelf Offering of up to $200 Mln- SEC Filing

ReutersDec 20 17:28 ET

CASI Pharmaceuticals Faces Evomela License Termination Dispute

TipRanksDec 16 08:27 ET